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Abstract 
Emerging experimental and human evidence has linked altered hepatic cholesterol homeostasis and 
free cholesterol (FC) accumulation to the pathogenesis of non-alcoholic steatohepatits (NASH). 
This review focuses on cellular mechanisms of cholesterol toxicity involved in liver injury and on 
alterations in cholesterol homeostasis promoting hepatic cholesterol overload in NASH.  
FC accumulation injures hepatocytes directly, by disrupting mitochondrial and endoplasmic 
reticulum (ER) membrane integrity, triggering mitochondrial oxidative injury and  ER stress, and 
by promoting generation of toxic oxysterols, and indirectly, by inducing adipose tissue dysfunction. 
Accumulation of oxidized LDL particles may also activate Kupffer and hepatic stellate cells, 
promoting liver inflammation and fibrogenesis. 
Hepatic cholesterol accumulation is driven by a deeply deranged cellular cholesterol homeostasis, 
characterized by elevated cholesterol synthesis and uptake from circulating lipoproteins and by a 
reduced cholesterol excretion. Extensive dysregulation of  cellular cholesterol homeostasis by 
nuclear transcription factors sterol regulatory binding protein(SREBP)-2, liver X-receptor(LXR)-  
and farnesoid X receptor(FXR) plays a key role in hepatic cholesterol accumulation in NASH. The 
therapeutic implications and opportunities for  normalizing cellular cholesterol homeostasis in these 
patients are also discussed. 
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1. Introduction 
Nonalcoholic fatty liver disease (NAFLD)  affects 30% of the general adult population and 70-80% 
of diabetic and obese patients 1 . NAFLD encompasses a histological spectrum, ranging from 
simple steatosis (SS) to steatosis plus necroinflammation (nonalcoholic steatohepatitis, NASH). 
While SS is considered to have a benign hepatological prognosis, NASH confers a 1.8-fold higher 
mortality, largely accounted for by liver-related complications, and is a leading cause of liver 
transplantation 2, 3 . Furthermore, both histological subtypes confer an increased risk of type 2 
diabetes (T2DM) and  cardiovascular disease (CVD) 3 .  
The pathogenesis of NASH is unclear: the original “two-hit”  hypothesis theorized that a first “hit” , 
namely hepatic steatosis, determined by metabolic factors (obesity, T2DM,  dyslipidemia), 
sensitized the liver to  subsequent “second hits”, namely oxidative stress and proinflammatory 
cytokines, that cause hepatocellular injury and liver inflammation. The validity of this view has 
been recently challenged, and growing evidence suggests SS and NASH may actually be 2 separate 
diseases: in this “multi-parallel hit” model 4 ,  the accumulation of “lipotoxic/pro-inflammatory” 
lipid species interacts with proinflammatory factors to yield NASH since the beginning, while in the 
other cases the liver develops steatosis and remains free from inflammatory and fibrotic changes 
5 . The type of toxic lipids has been the subject of extensive research: experimental inhibition of 
hepatic TG synthesis6 and human hypobetalipoproteinemia, which does not progress to cirrhosis 
despite massive steatosis7, suggested  that hepatic triglyceride (Tg) accumulation is not per se toxic, 
but rather  protects the liver by buffering the accumulation of lipotoxic Tg  precursors. Consistent 
with this view, subjects who are able to store excessive fat as neutral cholesterol esters and TG 
develop steatosis but not  NASH and may be considered “good fat storers”, while subjects who are 
unable to synthesize neutral lipids  acccumulate toxic lipid species and develop progressive 
inflammation and fibrosis, leading to NASH. The search for the key  toxic lipid species then 
focussed  on free fatty acids (FFA), diacylglycerides, phospholipids (ceramides, sphingolipids), and 
most recently, free cholesterol (FC) 5 . Growing evidence  connects altered cholesterol homeostasis 
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and hepatic FC accumulation to the pathogenesis of NASH. In the first National Health and 
Nutrition Examination Survey, higher dietary cholesterol consumption independently predicted a 
higher risk of cirrhosis 8 , and epidemiological data connect an increased cholesterol intake to the 
risk and severity of NAFLD 9, 10 . In NAFLD patients, the development of NASH and fibrosis 
paralleled hepatic FC accumulation 11, 12  . Experimental induction of hepatic FC accumulation 
promoted steatohepatitis and  fibrosis 13, 14, 15  , while correction of  hepatic FC overload 
improved  liver disease severity in NASH 16, 17, 18, 19,  20,  21,  22,  23 . 
We will review cellular mechanisms of cholesterol toxicity involved in liver injury and alterations 
in cholesterol homeostasis promoting hepatic cholesterol overload in NASH. 
 
2. Mechanisms of cholesterol toxicity in NASH 
Similar to atherosclerosis, where the vessel wall endothelium, the infiltrating macrophages and the 
fibroblasts promote atherosclerotic plaque formation, in the liver hepatocytes, the resident 
macrophages Kupffer cells and the hepatic stellate cells (HSC)  are key mediators of liver injury 
and NASH. 
Altered cholesterol metabolism has several toxic effects on each of these cells,  promoting NASH 
through diverse mechanisms. With its large, rigid core, cholesterol molecule affects membrane 
organization and physical  properties by  modulating the coexistence of lipid-disordered and lipid-
ordered phases, which is a critical determinant of membrane bilayer permeability and fluidity.  
Within this context, it is essential to maintain a  physiological range of FC/phospholipid ratio in 
cellular membranes. Although the degree of saturation of the fatty acyl moieties of membrane 
phospholipids is the major determinant of the fluidity of lateral membrane domains, which consist 
of well-packed, detergent-resistant liquid-ordered rafts and more fluid, detergent-soluble liquid-
crystalline regions 24 ,  the interaction of the hydrophobic rings of cholesterol with these fatty acyl 
chains has important effects: in particular, the ability of cholesterol to pack tightly with saturated 
fatty acyl groups of membrane phospholipids allows the formation of liquid-ordered rafts. Thus, 
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cholesterol depletion causes marked disruption of these rafts, as in plasma membrane caveolae (see 
below) and, conversely, when the FC/phospholipid ratio rises above a physiological level, the 
liquid-ordered rafts may become too rigid, and the liquid-crystalline domains 
may begin to lose their fluidity. These events adversely affect certain integral membrane proteins 
with multiple membrane-spanning domains,  undergoing  conformational changes as part of their 
activity cycle, that require conformational freedom for proper function and that can be inhibited by 
a high FC/phospholipid ratio, including  plasma membrane constituents like Na+-K+ ATPase, 
adenylate cyclase, alkaline phosphatase, rhodopsin, and transporters for glucose, organic anions, 
and thymidine 24 . 
 
Accordingly, different cellular organelles have distinct and tightly regulated cholesterol content and 
lipid composition: while the plasma membrane (PM) has a high cholesterol concentration,  the 
endoplasmic reticulum (ER) and the mitochondria have a much lower cholesterol content (3–5% of 
the total cellular cholesterol) 25  and are  highly sensitive to membrane fluidity loss induced by 
cholesterol enrichment. 
 
2.1 Mitochondrial reduced glutathione (mGSH) pool depletion and oxidative 
injury  
Mitochondrial membrane 2-oxoglutarate carrier is a mitochondrial transmembrane protein carrier 
which transports GSH,  synthesized de novo in the cytosol, into the mitochondria 26 . Intact 
mitochondrial GSH (mGSH) stores are  essential for controlling reactive oxygen species (ROS) 
generation by cell death stimuli such as tumour necrosis factor(TNF)-  and Fas ligand 25 . 
2-oxoglutarate carrier is particularly sensitive to changes in mitochondrial membrane cholesterol 
content and fluidity: mitochondrial FC loading impairs GSH transport, depletes mGSH stores, 
promoting  mitochondrial ROS generation and lipid peroxidation.  The functional consequences are 
sensitization of hepatocytes to TNF- , permeabilization of mitochondrial membrane,  cytochrome c 
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release, hepatocyte necrosis and apoptosis(see glossary), which promote hepatic inflammation and 
NASH 27, 28 (Figure 1, panel A-B).  
 
2.2 Cholesterol-induced ER stress 
The ER is a membranous organelle with critical cellular functions 29, 30 : folding and 
posttranslational modifications of nascent proteins to achieve their proper conformation;  
phospholipid synthesis; storage of calcium ions for cellular signalling; drug metabolism by enzymes 
such as cytochrome P450.  
Several physiological, pharmacological, and pathological conditions, including ER FC 
accumulation, impair ER functions and protein folding capacity, resulting in a condition known as 
ER stress or unfolded protein response (UPR, see glossary), which  plays a central pathogenetic role 
in obesity-associated disorders, including NAFLD 31,  32 .  FC accumulation triggers ER stress by 
altering the critical FC-to-phospholipid ratio of the ER membrane, necessary to maintain its fluidity. 
The resulting stiffening of the ER membrane inhibits enzyme conformational changes and impairs 
ER activity, triggering ER stress  and eventually cell apoptosis.  Among the ER enzymes, the 
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) is particularly sensitive to minimal increases 
in ER cholesterol content, which impair the activity of this ATPase. As a result,  the physiologically 
high  intra-ER Ca2+  concentration falls and the ER folding capacity is impaired 33, 34 (Figure 1 
panel C-D).  
The importance of ER FC accumulation the for triggering ER stress has been recently documented 
in hepatocytes 35, 36 , where  ER membrane cholesterol accumulation, rather than total cellular 
cholesterol overload, induced hepatic ER stress, while hepatocyte ER cholesterol lowering by two 
independent approaches (cyclodextrin or zaragozic acid) resolved UPR 36 . 
2.3 Generation of toxic oxysterols  
Oxysterols are derived from hydroxylation of the side chain of  cholesterol  at   different positions 
(C7α, C27, C24S, C22R and C25) of the molecule by autooxidation or by specific 
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monooxygenases, mainly belonging to the cytochrome P-450 family (Table 1). The addition of 
hydroxyl to the cholesterol molecule confers hydrophilic properties to oxysterols and increases their 
propensity for intracellular esterification, allowing faster transfer to endoplasmic reticulum or an 
alternative strategy to excrete cholesterol by extra-hepatic tissues[37].Oxysterol are difficult to 
measure in biological samples, due to several reasons. their plasma or tissue levels may be ~ 10 000 
times lower than plasma cholesterol concentrations; additionally, oxysterols have a short half-life 
(1–62 h) and are unstable molecules, sensitive to auto-oxidation during isolation and extraction.  
Recently,  new techniques, including isotope-dilution gas chromatography-mass spectrometry using 
deuterium-labelled internal standards, allowed a better characterization of these molecules and 
enhanced our understanding of their biological actions. Oxysterols serve important functions:  
(a) as substrates for the formation of bile acids(BA) 37 ;   
(b) as mediators of reverse cholesterol transport whereby excess cholesterol is returned from 
peripheral tissues to the liver for excretion[37];  
(c) emerging evidence suggests oxysterols are natural ligands for  nuclear transcription factors liver 
X-receptor(LXR)-  and sterol regulatory binding protein(SREBP)s, master regulators of hepatic 
lipid  metabolism(Table 1-2, Figure 2), and may contribute to liver injury in NAFLD 38 . The 
oxysterols most extensively characterized in NAFLD include: 
-7-hydroxycholesterol (7OHC): The main metabolic pathway of bile acid formation starts from 
the 7α-hydroxylation of cholesterol by CYP7A, a liver-specific microsomal 
cytochrome P450  with limited substrate specificity. The 7α-hydroxylation of cholesterol is the rate 
limiting step in the neutral pathway to bile acids. This enzyme is regulated at the 
transcriptional level by bile acids recirculating to the liver via the 
enterohepatic circulation, which modulate CYP7A1 gene transcription in a feed-back loop 
involving the nuclear receptors Small Heterodimer Partner (SHP, NR0B2), Liver Receptor 
Homolog-1 (LRH-1/CPF/FTF, NR5A2), and FXR (Table 1-2)[37]. In  NASH, hepatic expression 
of CYP7A1 is reduced, resulting in an impaired activation of FXR, with potentially deleterious 
metabolic and proinflammatory effects (see section 3.6) 14 . 
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-27-hydroxycholesterol (27OHC): beside the main, or “classic”, biosynthetic pathway of BA, an 
“alternative” (or acidic) metabolic pathway has been recently elucidated, where the first step is 
represented by hydroxylation at position 27, catalyzed by sterol 27-hydroxylase (CYP27A1), a 
mitochondrial cytochrome P-450 characterized by broad substrate specificity and by broad tissue 
and organ distribution, including vascular endothelium, fibroblasts and  macrophages[37].  
27OHC not only acts as intermediate of BA synthesis, but could also modulate gene transcription in 
at least two manners, by preventing SREBP-2 activation or by upregulation of ABC 
transporter expression via LXRα receptor, eventually inhibiting cholesterol uptake and synthesis 
and promoting cholesterol excretion [37]. In  NASH, hepatic expression of CYP27A1 is reduced, 
which may enhance SREBP-2-mediated cholesterol synthesis and uptake and reduce cholesterol 
excretion by ABC transporters, further aggravating hepatic cholesterol overload (see section 
3.6) 14 . 
 
-7-chetocholesterol (7-KC): 7KC derives from auto-oxidation of cholesterol. Hepatic levels of 7KC 
are increased in animal models of NASH 38 , and physiological concentrations of this oxysterol  
triggered hepatocyte apoptosis and directly activated hepatic macrophages and HSCs to secrete 
proinflammatory and profibrogenic cytokines transforming growth factor (TGF)- 1, monocyte 
chemoattractant protein (MCP)-1 and tissue inhibitor of matrix metalloprotease(TIMP)-1 in vitro,  
further promoting liver injury in NASH 38 . 
-25-hydroxycholesterol (25OHC): 25OHC derives from cholesterol hydroxylation catalyzed by a 
specific cholesterol 25-hydroxylase, which is not a member of the cytochrome P450 family and 
belongs to a family of enzymes that utilize diiron cofactors. 25-OHC concentrations are 
physiologically low in human hepatocytes, where it is converted into bile acids, but its levels have 
been found to be elevated in plasma of NAFLD patients 39 .  
25OHC potently modulates hepatic lipid metabolism and inflammatory response by enhancing 
hepatocyte LXR/SREBP-1c-mediated  lipogenesis and by activating nuclear factor (NF)- B, a key 
proinflammatory nuclear regulator, thereby promoting hepatic steatosis and inflammation 40 . 
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25OHC also promotes secretion of proinflammatory cytokine IL-8 by hepatic macrophages, further 
contributing to liver inflammation in NASH 40  
The impact of current treatments on oxysterols is uncertain, and statins do not consistently affect 
oxysterol levels in NAFLD patients 39 . Therefore alternative approaches to modulate the action of 
toxic oxysterols are being evaluated, including the synthesis of antagonist oxysterols: in fact, 
different oxysterols have diverse and even opposite actions, and while 25OHC enhances lipogenesis 
and inflammation, 25-hydroxycholesterol-3-sulfate (25OHC3S), the sulphated derivative of 
25OHC,   synthesized from 25OHC by the cytosolic sulfotransferase SULT2B1b, had potent 
antilipogenic and anti-inflammatory effects in the liver 41 . Consistently, experimental hepatic 
SULT2B1b overexpression decreased lipogenesis,  steatosis and plasma lipids in NAFLD 42 . 
Similarly, another synthetic oxysterol 22(S)-hydroxycholesterol (22(S)-HC) reduced LXR-mediated  
lipogenesis and intracellular lipid levels and improved insulin resistance in human hepatocytes 43 .  
Finally, administration of 27OHC to low density lipoprotein receptor knockout (LDLR-/-) mice fed 
a high fat/high cholesterol diet reduced lysosomal cholesterol accumulation in Kupffer cells and 
improved hepatic inflammation 44 . 
Collectively, these data highlight the potential for modulation of oxysterol action in the treatment of 
NAFLD. 
 
2.4 Cholesterol-induced hepatic Kupffer cells and hepatic stellate cell (HSC) 
activation 
Kupffer cells (KCs) represent 20-25% of the non-parenchymatous cells in the liver.  Beside their 
essential role as phagocytes, KCs  are the primary source of hepatic pro-inflammatory and 
profibrogenic cytokines (including TNF-α and TGF- 1), and recruit circulating inflammatory cells 
into the liver, thereby playing a key role in the pathogenesis of  liver injury in NASH 45 . The role 
of cellular cholesterol overload in KCs activation has been  demonstrated in mice fed a high fat/high 
cholesterol diet, where  the accumulation of FC into the KCs was required for their activation to a 
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proinflammatory phenotype and NASH development 46 . As KCs lack cholesterol biosynthetic 
ability, they acquire cholesterol  from circulating cholesterol-rich lipoproteins.  The main pathway 
of cholesterol uptake by KCs is oxidized LDLs (oxLDLs) internalization through the scavenger 
receptors cluster differentiation protein( CD)36 and scavenger receptor A(SR-A): as plasma 
oxLDLs are markedly increased in metabolic syndrome and in NASH patients, particularly in the 
postprandial phase, scavenger-receptor-mediated uptake of these lipoproteins by may represent a 
major trigger for KC activation and liver inflammation 47 . Consistently, targeted inactivation of 
oxLDL uptake by KCs through genetic deletion of scavenger receptors or immunization with anti-
oxLDL antibodies restored a quiescent KC phenotype and reversed hepatic inflammation 48,49, 
50 .  
HSC are responsible for liver fibrogenesis in NASH. The ability of intracellular FC accumulation to 
directly activate HSCs through the toll-like receptor(TLR)-4-dependent pathway and trigger hepatic 
fibrogenesis has been well-documented in animal models of diet-induced and spontaneous 
intracellular cholesterol accumulation 51  (Figure 3).  The exact mechanisms promoting HSC 
cholesterol overload are partially understood, but observational and experimental data  support a  
role for oxLDLs uptake  through the scavenger receptor lectin-like oxidized LDL receptor-1(LOX-
1)  in mediating HSC activation and hepatic fibrosis in NASH 52, 53  . 
Collectively, these data indicate the inhibition of scavenger receptor-mediated uptake of oxLDL by 
KCs and HSCs is a potential therapeutic target for NASH. 
2.5 Adipocyte cholesterol imbalance and adipose tissue dysfunction 
Adipose tissue dysfunction  plays a key role in the pathogenesis of obesity-related disorders, 
including NAFLD. Key features of dysfunctional adipocytes  include resistance to the anti-lipolytic 
action of insulin  and a proinflammatory adipokine pattern(enhanced TNF- , IL-1, IL-6 and leptin 
and reduced adiponectin secretion),  resulting in an increased release of toxic FFA and 
inflammatory cytokines into the portal blood to the liver 54,  55  .  
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Adipose tissue is a major site of cholesterol storage: in obese individuals half the whole body 
cholesterol is stored as FC in adipocytes, largely in the cytoplasmic lipid droplet and in lower 
percentage in PM 56 , where it is concentrated in flask-like membrane invaginations called 
caveolae 57 . Caveolae are important signaling platforms, serving as a concentrating point for 
numerous signalling molecules, including insulin receptor and GLUT4, and depend for their 
stability and functionality on a high PM cholesterol  content: decreasing PM cholesterol below a 
critical threshold  increases PM fluidity and disrupts caveolae integrity and function 58 (Figure 
1,panel E-F). 
Compared with small lean fat cells, hypertrophied adipocytes are characterized by intracellular 
cholesterol overload, largely contained in the lipid droplet: however, while the 
cholesterol/triglyceride ratio within the lipid droplet remains constant and independent 
of adipocyte size 59 , hypertrophied adipocytes have a decreased  PM cholesterol concentration,  
due to a dilution of PM cholesterol across an  increased cell surface 60 .The relative PM cholesterol 
depletion has 2 functional consequences 58 : 
- the transcription  factor SREBP-2, which is particularly sensitive to PM cholesterol content, 
senses PM cholesterol dilution as a true cholesterol depletion and activates transcription of its target 
genes (Table 3, Figure 2-3),  further promoting cholesterol accumulation 58 . 
-PM cholesterol depletion disrupts  caveolae integrity and function,  impairs intracellular insulin 
signalling 61  and GLUT-4 translocation to PM 62, 63, 64  , and enhances secretion of 
proinflammatory cytokines(Figure1-3) 58, 65 . 
Importantly, these alterations were independently replicated by adipocyte PM cholesterol depletion 
through cholesterol synthesis inhibitors (i.e. statins) or selective PM cholesterol chelators (i.e. β-
methylcyclodextrin), and reversed by PM cholesterol normalization, confirming that relative  PM 
cholesterol depletion of hypertrophied adipocytes is important for adipose tissue dysfunction 57, 
58, 63 .  
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Mechanisms regulating  cellular cholesterol sensing in adipocytes are being investigated: while 
cytosolic cholesterol pool derives mostly from circulating lipoprotein uptake, PM cholesterol is 
exquisitely sensitive to de novo cholesterol biosynthesis, and cholesterol synthesis inhibitors 
disrupted adipocyte caveolae integrity, impaired insulin signalling and adiponectin secretion in vitro 
and in vivo 61, 66 . The impact of these unwanted effects on liver disease and glucose metabolism 
in statin-treated NAFLD patients warrants further assessment 67 . 
 
3. Dysregulated hepatic cholesterol homeostasis in NAFLD 
In hepatocytes, intracellular cholesterol homeostasis is mantained through a coordinate network 
involving cholesterol-sensors and nuclear transcription factors regulating cholesterol synthesis, 
esterification, uptake, intracellular transport and excretion(Table 1-2, Figure 2).  
The 2 main sources of cellular cholesterol are de novo synthesis and uptake from plasma 
lipoproteins. To reach different cellular compartments, cholesterol must exit the ER, where it is 
synthesized, the cytosolic lipid droplets, where cholesterol esters are stored, and the endocytic 
compartments, where lipoprotein uptake occurs. Furthermore, cellular cholesterol must also reach 
the ER resident nuclear transcription factors SREBP-2 and LXR-  to regulate its synthesis and 
uptake in a feed-back loop (Figure 2, Table 1-2). In NAFLD these steps of cholesterol homeostasis 
are extensively deregulated,  promoting cholesterol accumulation and toxicity. 
  
3.1 increased cholesterol synthesis 
HMG CoA reductase (HMGCoAR) is the rate-limiting enzyme in cholesterol biosynthesis. Hepatic 
HMGCR expression and activity are increased in NASH patients,  paralleling both the extent of 
hepatic FC accumulation and the severity of liver histology 11, 68 . The increased HMGCoAR 
expression in NASH derives from enhanced gene transcription by SREBP-2, the principal 
transcriptional activator of HMGCoAR. Furthermore,  HMGCoAR is also relatively 
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dephosphorylated in its active form, as a result of hepatic   microRNA(miRNA)34a overexpression 
(see glossary) 6, 69 . 
Statins are known HMGCoAR inhibitors: although these agents improved transaminases and 
radiological steatosis in NAFLD patients, their effect on liver histology has been evaluated only in 1 
small RCT, therefore preventing any definitive conclusion on the effect of these drugs on human 
disease 70 . Notably, statins seem to confer a significant cardiovascular protection in NAFLD:  in 
the prospective Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study, 
enrolling hypercholesterolemic subjects with established CAD,  statin-related CVD risk reduction 
was significantly greater (-68%)  in patients with NAFLD than in those without NAFLD, with a 
number needed to treat of 5 NAFLD patients to save 1 CVD event 22 .  
Among the other enzymes involved in cholesterol biosynthesis, a polymorphism in squalene 
synthase,  catalyzing the production of squalene from farnesyl pyrophosphate, was associated with 
NAFLD histological disease activity in a genome-wide association study 71 . Squalene synthase 
inhibitors are being devekoped as alternative, non-myotoxic cholesterol-synthesis inhibitors: 
unfortunately, the development of lapaquistat, the only drug evaluated in phase II/III trials, was 
terminated due to potential hepatotoxicity concerns 72 . 
 
3.2 increased cholesterol-rich lipoprotein uptake  
Several membrane receptors contribute to cholesterol-rich lipoprotein uptake by hepatic and 
extrahepatic tissues, including the  low density lipoprotein receptor (LDLR) for LDLs, the 
scavenger receptors CD36 and LOX-1 for oxLDLs, and the  scavenger receptor class B type I (SR-
BI). Beside mediating Kupffer and HSC activation by oxLDL(see above), dysregulated scavenger 
receptors contribute, together with LDLR,  to hepatocyte cholesterol accumulation in NAFLD. 
Hepatocyte LDLR expression is increased in NAFLD,  as a result of enhanced SREBP-2 
activation 11, 14, 15, 66 .  
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CD36 is a transmembrane receptor protein  expressed on a broad range of cells, where it binds 
different ligands and is finely regulated by a network of nuclear receptors (Table 1). Hepatic CD36 
expression  is increased and correlates with the severity of steatosis in animal and human NASH 14, 
73 . Furthermore, liver-specific CD36 overexpression induced, while deletion protected against the 
development of experimental hepatic steatosis and inflammation 46, 47, 74  (Table 1). 
The SR-BI mediates the bi-directional selective transfer of cholesterol from HDL to hepatocytes 
and from hepatocytes to bile, with the net result of increasing reverse cholesterol transport and 
excretion 75 . Unlike ABC-transporters, SR-BI does not bind ATP or use ATP hydrolysis to drive 
transfer. SR-BI transcription is down-regulated in NASH as a result of increased SREBP-2 
expression, thereby promoting whole-body cholesterol accumulation 14 . 
 
3.3 altered intracellular cholesterol transport and compartmentalization 
Due to its water-insolubility, cholesterol requires specialized mechanisms to move across organelles 
in the cytosol, involving either vesicles or nonvesicular transport mechanisms. The latter is the 
major route for cholesterol movement and  is mediated by  diffusible carrier proteins, which have 
hydrophobic cavities to bind and transport cholesterol across the cytosol. Dysregulation of  these 
carriers in NAFLD enhances FC accumulation and toxicity in specific cellular compartments. 
 
3.3.1 Steroidogenic acute regulatory (StAR) transfer proteins  
The steroidogenic acute regulatory lipid transfer (START) protein family is defined by the presence 
of a well-conserved 210 amino acid domain folding into a hydrophobic pocket to bind diverse lipid 
species. Among the 15 members of this family, the cholesterol-binding proteins  are StARD1/D3 
and StARD4/D5/D6 76 , that  bind cholesterol with a 1:1 stoichiometry and play an essential role in 
the delivery of cholesterol from late endosomes/lysosomes (LE/LY) to mitochondria(Table 1, 
Figure 2). 
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Compared to controls,  hepatic StAR protein expression is 7- and 15-fold higher  in patients with 
steatosis and NASH, respectively 11 . Little is known about the regulation of StAR proteins: 
StARD4 StARD5 are upregulated by SREBP-2 and  by ER stress 77 , respectively,  both 
mechanisms being operative in NASH. Notably, StAR inhibition improved hepatocyte 
mitochondrial FC overload and injury 78 , making StAR modulation a potential therapeutic target 
in NASH.  
 
3.3.2 Niemann-Pick  C1 (NPC1) and NPC2 proteins 
Niemann-Pick  C1 (NPC1)  is an integral transmembrane protein localized to the LE/LY membrane, 
while NPC2 is a soluble lysosomal protein. Both proteins are required for delivery of LDL-derived 
cholesterol from LE/LY to the ER, the main regulatory site of cholesterol metabolism,  and to other 
intracellular compartments 79 (Table 1). In NPC1/2 deficient cells, LDL-cholesterol is internalized 
normally, but it is retained in LE/LY, with 2 functional consequences: 
-failure to deliver cholesterol to the ER disrupts the feed-back inhibition of SREBP-2, which 
inappropriately upregulates cholesterol synthesis and uptake despite high cholesterol levels, 
aggravating hepatocyte cholesterol overload and toxicity(Figure 2). 
 -although cholesterol transport to ER is impaired, StAR-mediated FC delivery from LE/LY to 
mitochondria is preserved and upregulated by increased cholesterol availability in LE/LY 80 , 
thereby aggravating mitochondrial injury 81 . 
In functional NPC1/2 deficiency, the amount of tissue cholesterol accumulation depends on the rate 
at which each tissue obtains cholesterol through the LDLR pathway: the liver is responsible for the 
uptake of 80% of LDL-cholesterol and is a major target organ, together with the central nervous 
system(CNS). Homozygous NPC1/2 deficiency leads to the rare autosomal-recessive Niemann-Pick 
type C (NPC) disease, characterized by liver, spleen, and CNS cholesterol accumulation,  
hepatosplenomegaly, liver failure, neurodegeneration and premature death. Intriguingly, 
heterogygous NPC1/2 deficiency leads to NAFLD, weight gain and metabolic syndrome 
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experimentally 82  and a recent European genome-wide study linked NPC1 gene to early-onset and 
morbid adult obesity 83 . 
  
3.3.3 Oxysterol-binding proteins and OSBP-related proteins  
Oxysterol-binding proteins (OSBPs) and OSBP-related proteins (ORPs) are  a large (>12 members) 
family of soluble cytosolic lipid-binding proteins, sharing a common lipid-binding OSBP-related 
domain. Initially identified for their oxysterol-binding capacity 84 , these proteins were 
subsequently discovered to play key roles in numerous steps of lipid metabolism, including 
cholesterol delivery from LE/LY to ER, cholesterol shuttling between PM and ER, and intracellular 
signalling 85 . ORP8, a member of this family,  plays a relevant role in  lipid homeostasis and 
insulin sensitivity: its overexpression reduced, while silencing increased,  hepatic cholesterol and 
triglyceride accumulation by modulating SREBP-2 and SREBP-1c expression 86 . ORP8 also 
enhances hepatic insulin sensitivity through an AKT-mediated mechanism 87 , and its expression is 
reduced in obesity via a miRNA143-dependent pathway 83 . 
 
3.4 altered cholesterol absorption and secretion 
3.4.1 Niemann-Pick C1 like 1 protein 
Daily cholesterol intake in humans on a typical Western diet is 300–500 mg, and daily biliary 
secretion of cholesterol from the liver into the gut is  800–1200 mg, of which 50% is reabsorbed in 
the intestine and delivered to the liver, in a process  resembling enterohepatic bile acid 
circulation 88 .  NPC1-like 1 protein (NPC1L1)  is expressed on the apical surface of enterocytes 
and on the canalicular membrane of hepatocytes and mediates active cholesterol absorption from 
gut lumen and from the bile, respectively(Table 1, Figures 1-2).. NPC1L1 is a N-glycosylated  
integral membrane protein with a sterol-sensing domain (SSD), which regulates NPC1L1 
intracellular cycling by sensing membrane cholesterol content: when cells are enriched with 
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cholesterol 85 , NPC1L1 localizes predominantly to the endocytic recycling compartment (ERC); 
when cells are deprived of cholesterol, NPC1L1 moves to the plasma membrane.  
Genetic deletion or pharmacological inhibition of NPC1L1 by  ezetimibe disrupt enterohepatic 
circulation of cholesterol,  causing a substantial endogenous cholesterol loss and 
a feedback up-regulation of endogenous cholesterol synthesis, which however cannot fully 
compensate for the excessive cholesterol loss, as NPC1L1 deficiency or ezetimibe 
treatment significantly reduce blood cholesterol in rodents on low-cholesterol diets 89  and in pure 
vegetarians 90 . Preliminary experimental and human evidence  suggest ezetimibe may  effective 
reduce steatosis, necroinflammation and fibrosis in NASH 18, 19, 20 . Additional mechanisms 
beyond inhibition of cholesterol absorption may underlie the observed benefits of  ezetimibe in 
NAFLD: NPLC1L1  down-regulates  NPC2 expression, thereby promoting LE/LY FC 
overload 91 ; ezetimibe restores hepatic microsomal triglyceride transfer protein (MTTP) 
expression, which is required for hepatic VLDL-Tg  secretion 18, 92 ; finally, ezetimibe may 
synergize with -glucosidase inhibitors to enhance intestinal incretin  glucagon-like peptide-1 
secretion and peroxisome proliferators-activated receptor- 1 (PPAR- 1) activation 93, 94, 95 .  
As  intestinal cholesterol absorption seems to be decreased in NAFLD patients 38, 96 , the relative 
contribution of intestinal vs. hepatic NPC1L1 inhibition was evaluated to explain the observed 
benefits in NAFLD: selective hepatic NPC1L1 inhibition increased biliary cholesterol excretion,  
attenuated mitochondrial cholesterol overload, restored mGSH levels, reduced ROS generation, c-
JUN N-terminal kinases (JNK)  activation, and ER stress, eventually  improving hepatic steatosis 
and insulin resistance 97, 98  .Collectively, these data indicate hepatic NPC1L1 inhibition  is a 
crucial mediator of  the benefits of ezetimibe in NASH.  
Despite these premises, some issues needs to be addressed: experimental data suggest ezetimibe 
biliary excretion is reduced in NASH, which may reduce its disposition and bioactivity 99 ; the 
impact of background cholesterol intake on ezetimibe effectiveness is unclear 100 ; finally, the 
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potential synergism with statins on liver 101  and cardiovascular disease, the other major health-
related issue in NAFLD, is unknown and require further investigation. 
 
3.4.2 ATP-binding cassette (ABC) transporters and cellular cholesterol efflux 
 ABC transporters are a family of integral membrane proteins that actively transport a variety of 
small molecules across cell membranes. In mammals, at least four ABC-transporters mediate sterol 
efflux from cells: ABCA1, ABCG1, ABCG4, and ABCG5/ABCG8.  
ABCA1 can be found in several celli lines, including macrophages and hepatocytes: in the latter, it 
localizes to the basolateral membrane, in contact with the sinusoidal vasculature, where it  catalyzes 
the transfer of cellular cholesterol and phospholipids to lipid-free apolipoprotein I (apoA-I) to form 
HDL particles. Lipidation of apoA-I by ABCA1 is the rate-limiting step in reverse cholesterol 
transport and complete loss of ABCA1 function causes Tangier disease,  characterized by HDL 
deficiency, sterol tissue accumulation, and atherosclerosis. While most  studies on ABCA1 focused 
on its relationship with atherosclerosis, recent data suggest a reduced hepatocyte ABCA1 activity 
contributes to hepatic cholesterol accumulation and injury in NASH 14, 66 . Consistently,  even 
minor (50%) loss of ABCA1 function  in hepatocytes promoted FC overload and NASH, while 
ABCA1 overexpression improved liver disease experimentally 102 .  
ABGC5 and ABCG8 are ‘half-transporters’ that form an heterodimer (ABCG5/G8) on the apical 
membrane of enterocytes and on the canalicular membrane of hepatocytes, to efflux plant and 
animal sterols into the intestinal lumen and the bile, respectively, thereby  opposing the activity of  
NPC1L1. The importance of ABCG5/G8 transporters in limiting cholesterol and phytosterols 
accumulation is exemplified  by sitosterolemia, a rare autosomal recessive disorder characterized by 
ABCG5 or ABCG8 function loss,  tissue accumulation of plant sterols (mainly β-sitosterol), 
hypercholesterolemia, tendon xantoma and premature atherosclerosis.  
Recent animal and human data found a reduced  ABCG5/G8 expression in NASH 14, 66 , and the 
relevance of ABCG5/G8 for hepatic cholesterol homeostasis and NASH has been elucidated in 
transgenic mice: ABCG5/G8 knockout induced steatosis, hepatocyte apoptosis, ER stress and 
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hepatic insulin resistance, accelerating high-fat diet-induced NASH 103 .  These experiments 
highlighted also the importance of intestinal cholesterol absorption for whole-body cholesterol 
balance: liver-specific ABCG5/G8 over-expression alone failed to induce a net cholesterol loss, as  
excreted biliary cholesterol was reabsorbed by intestinal NPC1L1. Conversely, hepatic ABCG5/8 
over-expression plus NPC1L1 inhibition by ezetimibe induced hepatic cholesterol loss and   
reduced atherosclerosis, indicating that increased biliary cholesterol secretion must be  coupled with 
decreased intestinal cholesterol absorption to promote net sterol loss from the body 104 . 
 
3.5 altered intracellular cholesterol esterification and de-esterification  
Newly synthesized cholesterol is esterified and de-esterified according to cellular requirements by 2 
ER enzymes, acyl-CoA cholesterol:cholesteryl transferase (ACAT)-2 and cholesteryl ester 
hydrolase (CEH), respectively.  
In NAFLD, hepatocyte ACAT-2 activity is mildly increased 11, 14  , unchanged 66  or 
reduced 105 , while  CEH is 6-fold higher than in healthy controls 66 .  The net effect of ACAT-2 
and CEH activity on cellular cholesterol balance critically depends on a functioning cholesterol 
efflux machinery, represented by ABC transporters. In hepatocytes and macrophages, hydrolysis of 
CE is a required step for CE mobilization and excretion; consistently, hepatocyte-specific ACAT-2 
deletion prevented cholesterol accumulation and steatosis 106 ,  and transgenic CEH 
overexpression in hepatic macrophages reduced cellular cholesterol overload, improving hepatic 
insulin resistance and inflammation 107, 108 .  However, if ABC transporter-mediated cholesterol 
efflux is impaired as in NAFLD 14, 66 , inappropriate CEH activation enhances FC accumulation 
and toxicity (Table 1).  
 
3.6 Nuclear regulators of cholesterol homeostasis 
The processes described above are co-ordinately regulated by nuclear transcription factors, 
molecules that, upon ligand binding,  bind to specific promoter regions, named response elements 
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(REs), of target genes and regulate transcription of their products. Three nuclear transcription 
factors regulating cholesterol metabolism have been linked to NAFLD: sterol regulatory element-
binding protein(SREBP)-2, farnesoid X receptor (FXR), and liver X-receptor(LXR). 
3.6.1 Sterol regulatory binding protein(SREBP)-2   
Verterbate genomes contain 2 loci, named sterol regulatory element-binding factor (SREBF)-1 and 
SREBF-2, which code for SREBP-1, a key regulator of  fatty acid synthesis,  and for SREBP-2,  a 
master regulator of cholesterol metabolism 109 : under low cellular cholesterol levels, SREBP-2 is 
activated and translocates from the ER to the nucleus, where it modulates transcription of target 
genes involved in cholesterol synthesis, uptake, secretion and transport, to increase intracellular 
cholesterol availability. Conversely, cellular cholesterol repletion retains SREBP-2 in the ER and 
prevent its activation(Figure 2, Table 2). 
Beside SREBP-2, the SREBPF-2 locus also generates the microRNA miRNA-33a, which is 
processed from an intron within the SREBF2 primary transcript 107 : miRNA-33a inhibits 
ABCA1-mediated cholesterol export,  decreases NPC-1, and reduces the expression of several 
enzymes involved in mitochondrial fatty acid -oxidation 110 . Therefore,  the physiological 
activation of SREBP-2/miRNA33a  under low cholesterol conditions promotes cholesterol 
synthesis and retention and increases availability of fatty acids to promote storage of neutral  lipids 
CE and triglycerides. SREBP-2 is inappropriately activated despite cellular cholesterol overload in 
NAFLD, with hepatic SREBP-2 activity being 7- and 3-fold higher in NASH and steatosis patients 
than in controls 11, 14, 66 . Potential reasons for inappropriate SREBP2 activation in NAFLD 
include: 
-direct stimulatory effect of hyperinsulinemia 14, 111  and  proinflammatory cytokines 15, 112 : in 
conditions of chronic low-grade inflammation and hyperinsulinemia, like obesity and insulin 
resistance, the suppressive effect of elevated cellular cholesterol levels on SREBP-2 expression is 
overridden by high insulin and proinflammatory cytokine levels, which disrupt the physiological 
negative feed-back by cholesterol stores and activate directly SREBP-2 15  (Figure 2). 
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-downregulation of hepatic miRNA122: miRNA-122 (see glossary) is the most abundant  miRNA 
in the liver, where it regulates the expression of nearly 200 genes 67 , including SREBP-2, which is 
repressed by miRNA122. Hepatic miRNA 122 is strongly downregulated in NASH patients, and 
replicating miRNA-122 suppression significantly increased expression of  SREBP-2 and its target 
genes  in vivo and in vitro 67 . 
-genetic variation in SREBP-2 activity:  a  polymorphism  in SREBP-2  recently predicted the 
incidence and severity of NAFLD and  of coexisting  glucose and lipid dysmetabolism in a cohort 
of initially lean, insulin sensitive subjects 113 . 
Collectively, these data highlight the importance of SREBP-2/miRNA33a complex for hepatic 
cholesterol metabolism, demonstrating its inappropriate upregulation may be crucial for hepatic 
cholesterol overload in NASH and suggesting its modulation may be a therapeutic target for NASH.   
 
3.6.2 Farnesoid X receptor   
Originally known for its function of bile acid sensor in enterohepatic tissues,  farnesoid X receptor 
(FXR) has recently emerged as a master regulator of lipid and glucose homeostasis and of 
inflammatory and fibrogenic processes at hepatic and extrahepatic level. In the liver,  FXR 
promotes cholesterol excretion by ABCG5/G8 transporters 114 , triglyceride clearance by 
increasing fatty acid β-oxidation and suppressing lipogenesis, and has enhances insulin-sensitizing, 
anti-inflammatory and anti-fibrotic properties 115 (Table 2). In NAFLD patients,  hepatic FXR 
activity and  bile acid biosynthesis are decreased and inversely related to the severity of liver 
histology 14, 66, 103  and, consistently,  FXR-deleted mice on a high fat diet exhibit massive 
hepatic steatosis, necroinflammation and fibrosis, all reversed by  FXR agonists 116, 117 . On this 
basis a novel class of potent, semi-synthetic bile acid  FXR agonists is being evaluated for the 
treatment of obesity-related disorders, including NAFLD.  One of these compounds, obeticholic 
acid (OCA), a semi-synthetic derivative of chenodeoxycholic acid,  ameliorated liver fibrosis 
markers, insulin resistance, and weight gain in  a phase IIa RCT enrolling diabetic NAFLD 
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subjects 118  and is currently evaluated in the multicenter, double-blind  randomized “FXR Ligand 
NASH Treatment (FLINT)” trial (www.clinicaltrials.gov NCT01265498). 
 
3.6.3 Liver X receptor(LXR)-  
There are two LXRs, LXR-  and LXR- , with considerable sequence homology and the same 
ligand binding, but with different tissue distribution: LXR  is highly expressed in the liver, adipose 
tissue and macrophages, whereas LXR  is expressed in many tissues 119, 120 . Originally 
identified for their function of  nuclear cholesterol sensors activated in response to elevated 
intracellular oxysterols, LXRs were subsequently shown to be activated also by glucose 119 . To 
regulate transcription of its target genes,  LXR must form an  heterodimer with another nuclear 
receptor, the retinoid X receptor (RXR) which is ligand-activated by 9-cis retinoic acid. 
LXR-  is a key regulator of whole-body cholesterol  metabolism: upon activation, LXR-   
increases the expression of ABCA1, ABCG5/G8 in  macrophages, hepatocytes and enterocytes and 
downregulates intestinal NPC1L1 expression,  thereby promoting reverse cholesterol transport and 
intestinal excretion 119 . Furthermore, LXR-  increases the hepatic trascription of cytochrome 
P450 7A1 (CYP7A1),  the rate-limiting enzyme in bile acid synthesis,  promoting cholesterol 
conversion to bile acids, and accelerates LDL-receptor degradation, thereby reducing hepatocyte 
cholesterol uptake 121 . Beside its key role in promoting net cholesterol loss from the body, LXR 
has also direct anti-inflammatory effects, and LXR  agonists improved hepatic inflammation and 
fibrosis by reducing cholesterol-induced activation of Kupffer  and HSCs in animal models of 
NASH 13, 122, 123 . 
Despite these benefits, LXR   has a drawback: LXR   activation upregulates hepatic lipogenesis 
and inhibits VLDL catabolism, promoting hepatic steatosis, large VLDL triglyceride production 
and hyperlipidemia 120, 124, 125, 126, 127  (Table 2). Although the increased storage of neutral 
triglycerides may actually buffer the lipotoxic FC and free fatty acids and protect against the 
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development of NASH, the impact of resulting hyperlipidemia  on CVD risk  hampers the clinical 
application of LXR agonists for treatment of NAFLD at present.  
 
4. Future perspectives 
There is an unmet need for a safe and effective treatment for NASH: TZDs reverse 
necroinflammation and slow fibrosis progression, but promote weight gain; vitamin E improves 
NAFLD activity, but its impact on lipid and glucose metabolism is uncertain 70 . The pathogenesis 
of NASH is not fully elucidated, and emerging evidence suggest it can dissociate from insulin 
resistance and metabolic syndrome 128 . The data presented suggest NAFLD is associated with 
extensive derangement in numerous steps of hepatic cholesterol homeostasis, which converge to 
promote FC accumulation and toxicity, and eventually NASH. Pharmacological modulation of 
cholesterol homeostasis is therefore an attractive therapeutic option for NASH, not only for 
ameliorating liver disease, but also to reduce CVD risk, which is the other health-related burden in 
NAFLD 3, 22 . Current  therapeutic options  targeting cholesterol metabolism include inhibition of 
HMGCoAR by statins and of NPC1L1 by  ezetimibe. Despite their established cardiovascular 
benefit, data on  statin efficacy in NAFLD are sparse due to the feared hepatotoxicity of these 
drugs. However, current data demonstrated patients with hepatic steatosis do not seem at increased 
risk for statin hepatotoxicity 129 : on the basis of available evidenced,  the Liver Expert Panel 
stated that statins can be safely used in patients with NAFLD and routine liver enzyme monitoring 
is not warranted in this population 130 .  
While the efficacy of these drugs warrants evaluation in large RCTs with histological end-points 
and clinical outcomes, other approaches targeting cholesterol-induced liver injury are being 
evaluated, including GLP-1 analogues, which reduced cholesterol synthesis and hepatic 
inflammation in  methionine choline deficient (MCD) dietary models of  NASH 131 , hepatic 
thyroid receptor beta-agonists 132 , antisense nucleotides modulating miRNA22a activity 109 , 
strategies enhancing the cellular cholesterol-unloading and anti-inflammatory properties of HDL 
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particles 133 , and agonists/antagonists of key nuclear regulators of cholesterol metabolism like 
FXR, SREBP-2. These approaches are currently evaluated in preclinical studies or phase II trials 
and promise to  open up new avenues for the development of therapeutics for NASH and associated 
disorders. 
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FIGURE LEGENDS 
 Figure 1: mechanisms of membrane cholesterol toxicity operating in hepatocytes (panel A-D) 
and adipocytes (panel C-F) 
 
Panel A: intact mitochondrial glutathione (mGSH) stores are  essential for controlling reactive 
oxygen species (ROS) generation by cell death stimuli such as  tumour necrosis factor(TNF)-  and 
Fas ligand (FasL) in hepatocytes .GSH is exclusively synthesized in the cytosol and is transported 
into the mitochondria by the mitochondrial transmembrane 2-oxoglutarate protein carrier (2-OG).  
Panel B: 2-OG carrier is particularly sensitive to changes in mitochondrial membrane cholesterol 
content and fluidity: when mitochondria are loaded with free cholesterol, mitochondrial GSH 
(mGSH) transport by 2-oxoglutarate (2-OG) carrier is impaired, resulting in mGSH depletion. GSH 
depletion enahnces the generation of ROS in response to TNF-  and Fas ligand (FasL),  causing 
cardiolipin (CL) peroxidation (CLOOH), which destabilizes the mitochodrnial membrane lipid 
bilayer. Mitochondrial membrane  destabilization and  permeabilization result in  cytochrome c (Cyt 
C) release and trigger of hepatocyte necrosis and apoptosis. Consistent with these model, the 
replenishment of mGSH by permeable precursors, such as GSH ethyl ester, protected mitochondrial 
cholesterol-loaded hepatocytes against TNF/Fas-mediated apoptosis. Furthermore, hepatocytes 
selectively depleted of mGSH reproduced the sensitization to TNF/FasL observed in the nutritional 
and genetic models of hepatic steatosis characterized by cholesterol accumulation.  
Collectively, these data demonstrate that mitochondrial FC accumulation induces oxidative injury 
and sensitizes hepatocytes to the action of pro-inflammatory/proapoptotic agents 
Panel C: the ER is a membranous organelle with critical cellular functions: folding and 
posttranslational modifications of nascent proteins to achieve their proper conformation;  
phospholipid synthesis; storage of calcium ions for cellular signalling; drug metabolism by enzymes 
such as cytochrome P450. A high intra-ER  Ca2+ concentration is necessary for maintenance of 
normal ER function and protein folding ability. This high Ca2+ concentration of ER is actively 
maintained by the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA).  
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Panel D: FC accumulation triggers ER stress by altering the critical FC-to-phospholipid ratio of the 
ER membrane, necessary to maintain its fluidity when the FC:phospholipid ratio in the ER 
membrane reaches a critical threshold of stiffness, integral ER membrane proteins become inactive. 
Among the ER enzymes, the SERCA ATPase is particularly sensitive to minimal increases in ER 
membrane cholesterol content: the resulting stiffening of the ER membrane inhibits SERCA 
conformational changes and activity, leading to a fall in  the physiologically high  intra-ER Ca2+ 
concentration and  impairing ER function and folding capacity(ER stress). ER stress or unfolded 
protein response (UPR, see glossary)  plays a central pathogenetic role in obesity-associated 
disorders, including NAFLD.  
The importance of FC accumulation the for triggering ER stress has been recently documented in 
hepatocytes where  ER membrane cholesterol accumulation, rather than total cellular cholesterol 
overload, induced hepatic ER stress, while hepatocyte ER cholesterol lowering by two independent 
approaches (cyclodextrin or zaragozic acid) resolved ER stress. 
The relevance of dysfunctional SERCA  for free cholesterol-induced hepatocyte apoptosis and the 
pathogenesis of NAFLD and diabetes has recently emerged: in obese diabetic mice , where  
hepatic SERCA expression is dramatically reduced and normalization of SERCA activity in the  
liver alleviates ER stress, reduces lipogenesis, and improves  glycemia and NAFLD . 
Panel E: in adipocytes, cholesterol is largely contained in the cytoplasmic lipid droplet and in lower 
percentage in plasma membrane (PM), where it is concentrated in flask-like membrane 
invaginations called caveolae, which represent as much as 50% of the plasma membrane. These  
specialized membrane microdomains have a unique composition in that they are highly enriched in 
cholesterol and their coat proteins caveolins (-1, -2, and -3) and caveins (-1 and -2). Caveolae 
concentrate numerous signalling molecules, including insulin receptor(IR) and GLUT4, and depend 
for their stability and functionality on a high PM cholesterol  concentration: lowering PM 
cholesterol below a critical threshold  increases PM fluidity and disrupts caveolae integrity and 
function. 
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Panel F: compared with small lean fat cells, hypertrophied adipocytes from obese subjects are 
characterized by intracellular cholesterol overload, largely contained in the lipid droplet: however, 
while the cholesterol/triglyceride ratio within the lipid droplet remains constant and independent 
of fat cell size, hypertrophied adipocytes have a decreased  PM cholesterol concentration,  due to a 
dilution of PM cholesterol across an  increased cell surface.The relative PM cholesterol depletion 
activates the transcription  factor SREBP-2 further promoting cholesterol accumulation within the 
fat cell, and disrupts  caveolae integrity and function,  impairing intracellular insulin signalling and 
GLUT-4 translocation to PM, and enhancing secretion of proinflammatory cytokines including  
angiotensinogen, chemerin, TNF-  and IL-6. 
These alterations were independently replicated by adipocyte PM cholesterol depletion through 
cholesterol synthesis inhibitors (i.e. statins) or selective PM cholesterol chelators (i.e. β-
methylcyclodextrin), and reversed by PM cholesterol normalization, confirming that relative  PM 
cholesterol depletion of hypertrophied adipocytes is an important determinant of adipose tissue 
function. 
Mechanisms regulating  cellular cholesterol sensing in adipocytes are being investigated: while 
cytosolic cholesterol pool derives mostly from circulating lipoprotein uptake, PM cholesterol is 
exquisitely sensitive to de novo cholesterol biosynthesis, and cholesterol synthesis inhibitors 
disrupted adipocyte caveolae integrity, impaired insulin signalling and adiponectin secretion in vitro 
and in vivo. The impact of these unwanted effects on liver disease and glucose metabolism in statin-
treated NAFLD patients may be clinically relevant and warrants further assessment. 
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Figure 2: hepatocyte cholesterol homeostatic mechanisms involved in the pathogenesis of 
NAFLD 
In hepatocytes, LDL particles are internalized via receptor-mediated endocytosis by LDL receptors 
(LDLR), and the resulting vesicles deliver their contents to early endosomes, where the acid lipase 
enzyme  hydrolyzes LDL-derived cholesterol esters (CE ) to free cholesterol (FCHOL). Then 
LDLR, devoid of their cholesterol cargo,  returns to  basolateral plasma membrane (PM), while 
cholesterol is transported from early to late endosomes (LE), which fuse with Golgi-derived 
vesicles containing hydrolytic enzymes and  mature into lysosomes (LY). Intracellular cholesterol 
transport from  LE/LY to cellular organelles and membranes is predominantly mediated by  protein 
carriers (nonvescicular transport): the steroidogenic acute regulatory lipid transfer (StAR) proteins 
are essential for FCHOL delivery to mitochondria, while the Niemann-Pick  C1 (NPC1) and the 
NPC2 are required for delivery to the ER, the main regulatory site of cholesterol metabolism,  and 
to other intracellular compartments. Oxysterol-binding proteins (OSBPs)-related proteins (ORPs), 
and specifically ORP8, have been implicated in FCHOL  delivery from LE/LY to ER and  
cholesterol shuttling between PM and ER. Functional deficiency of NPC1/2 carriers leads to LE/LY 
FCHOL accumulation, which is transported by StAR to mitochondria, and fails to downregulate 
sterol regulatory binding protein(SREBP)-2 in the ER, disrupting the negative feed-back on 
SREBP-2 regulated cholesterol synthesis and uptake and  resulting is FCHOL accumulation and 
toxicity. 
In the ER, cholesterol regulates expression of nuclear transcription factor SREBP-2, which is 
expressed as an inactive precursor protein. Under low intracellular cholesterol conditions, SREBP-2 
binds its chaperone SREBP cleavage activating protein (SCAP) and translocates  to the Golgi 
apparatus, where it is cleaved and activated by two proteases, site-1 serine protease and site-2 
metalloproteinase. Conversely, in response to heightened cellular cholesterol levels, the SCAP 
changes conformation and binds to insulin-induced gene-1(Insig-1) and -2, which  retains the 
SREBP-2/ SCAP complex within the ER.  
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The active SREBP-2 enters the nucleus, where it modulates transcription of key target genes 
involved in cholesterol homeostasis (Table 1-2)  
In NASH, as a result of increased ER free cholesterol content, the ER membrane stiffens  and 
prevents conformational changes of the, which is necessary for maintaining high  intra-ER Ca2+  
concentrations. As a result of the  sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 
dysfunction, intra-ER Ca2+  levels fall and the normal functions and folding ability of the ER are 
impaired,  triggering ER stress. In response to ER stress, three stress-sensing proteins found on the 
ER membrane: PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol-requiring kinase-
1α (IRE-1α), and activating transcription factor-6 (ATF-6) are activated and initiate a series of 
adaptive mechanisms, named  unfolded protein response (UPR) .  If ER stress conditions persist, 
however,  ER triggers cell death through caspase-dependent (apoptosis) and caspase-independent 
(necrosis) mechanisms 
A major pathway of cholesterol metabolism in hepatocytes is the synthesis of oxysterols and bile 
acids. Oxysterols are a class of oxygenated derivatives of cholesterol formed by autooxidation or by 
specific monooxygenases, mainly of the cytochrome P450(CYP450) family.  
The microsomal sterol 7  hydroxylase (CYP7A1) catalyzes the 7α-hydroxylation of cholesterol to 
7α-hydroxycholesterol (7OHC),  the rate limiting step in the neutral pathway to bile acid synthesis, 
while the mitochondrial   sterol 27-hydroxylase (CYP27A1) catalizes the “alternative” (or acidic)   
pathway of bile acids synthesis, leading to 27-hydroxycholesterol (27OHC).  
A third, quantitatively minor pathway involves sterol 25-hydroxylase, which catalyzes cholesterol 
25-hydroxylation to 25-hydroxycholesterol (25OHC). 
Beside being early intermediates in the synthesis of bile acids, oxysterols are important modulators 
of nuclear transcription factors: 27-OHC represses SREBP-2-mediated cholesterol synthesis and 
stimulates LXR- -mediated transcription of ABCA1 transporters, thereby promoting cholesterol 
excretion, while  25OHC activates  LXR /SREBP-1c-mediated lipogenesis, further enhancing free 
fatty acid  (FFA) accumulation and toxicity,  and inflammatory response via NF- B activation, and 
has been recently implicated in liver injury in NASH  
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Conversely, 25-hydroxycholesterol-3-sulfate (25OHC3S), the sulphated derivative of 25OHC,   
synthesized by the cytosolic sulfotransferase SULT2B1b through sulfation of 25OHC, had potent 
and opposite effects on hepatic lipid metabolism and ameliorates steatosis and inflammation in 
experimental NASH 
The synthesis of bile acid is activated by the farnesoid X receptor (FXR), which also promotes 
cholesterol excretion through ABCG5/G8 transporters and  inhibits SREBP-1c-mediated 
lipogenesis and NF- B-mediated inflammatory pathway.  
In NASH,  hepatic FXR expression and  bile acid biosynthesis are decreased. 
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Figure 3: interactions among adipocyte, hepatocyte, hepatic stellate cell (HSC) and Kupffer 
cell in promoting cholesterol-mediated liver injury in NAFLD 
Intracellular cholesterol accumulation induces a series of events in adipocytes and liver cells  
collectively promoting liver injury and NAFLD.  
In hypertrophic adipocytes, cholesterol imbalance (and specifically, plasma membrane, PM, 
cholesterol depletion) upregulates SREBP-2, further promoting cholesterol accumulation, and 
disrupts  caveolae integrity and function,  impairs insulin receptor (IR)36 and GLUT-4 translocation 
to plasma membrane 
Free cholesterol (FCHOL) accumulation in obese adipocytes enhances secretion of 
proinflammatory cytokines, including  angiotensinogen, chemerin, TNF-  and IL-6 which, together 
with elevated plasma insulin levels,  downregulation of miRNA122  and possibly functional 
SREBF2 gene polymorphisms, disrupt the physiological negative feed-back by elevated cholesterol 
stores and activate directly SREBP-2 in hepatocytes.  
In the liver, Kupffer cells accumulate FCHOL through uptake of oxidized LDLs by scavenger 
receptors CD 36 and SR-A and become activated, secreting proinflammatory adipokines (IL-1, 
TNF- ) and the profibrogenic cytokine Transforming Growth Factor(TGF)-β1, which activates  
 hepatic stellate cells (HCS),  promoting hepatic fibrosis. 
The ability of intracellular free cholesterol overload to directly activate HSCs, without the 
mediation of KCs through the toll-like receptor(TLR)-4-dependent pathway and trigger hepatic 
fibrogenesis has been well-documented in  mice on high-cholesterol diets and in Niemann–Pick 
type C1-deficient mice, the latter spontaneously accumulating intracellular free cholesterol . 
HSC  accumulate cholesterol through oxLDLs uptake by LOX-1 receptors and possibly by other yet 
poorly characterized receptor and non-receptor pathways.  
High intracellular cholesterol levels up-regulates toll-like receptor(TLR)-4, which in turn down-
regulates, through the adaptor molecule MyD88, the membrane receptor Bambi, a pseudoreceptor 
for TGF-β1 with negative regulatory function. The removal of this inhibitor sensitizes HSC to 
activation by TGF-β1 and secretion of chemotactic factors monocyte chemotactic protein-1 (MCP-
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1) and macrophage inflammatory protein 1  (MIP1 ), that recruit circulating macrophages to the 
liver to become Kupffer cells. Kupffer cells, in turn, secrete TGF-β and further activate HSC in a 
paracrine manner. 
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Cholesterol synthesis 
Biological effect 
HMGCoAR expression and activity in hepatocytes are 
inappropriately elevated in NAFLD and correlate with 
the severity of liver histology68 
Opposite from HMGCoAR inhibition, squalene 
synthase inhibition causes the accumulation of 
isoprenoid intermediates (isopentenyl-PP, farnesyl-
PP), precursors for signaling molecules regulating 
protein synthesis, mitochondrial respiration 
(ubiquinone, coenzyme Q10), and glycosylation 
Cholesterol-rich lipoprotein uptake 
Biological effect 
 LDL receptor is inappropriately overexpressed in 
NAFLD and correlates with the severity of liver 
histology11, 14, 15,  68, 112 
Hepatocyte CD36 membrane expression is increased and 
correlates with steatosis and insulin resistance in NAFLD 
patients73. 
 The hepatic CD36 deletion reversed NASH 48, 49, 74 
 
Upon oxLDL-binding, LOX-1 triggers HSC-mediated 
fibrogenesis(52 
SNP in LOX-1 correlated with the risk of severity of 
NASH in humans 53 
Function 
catalyzes the conversion of HMGCoA 
to mevalonate,  rate-limiting step in 
cholesterol biosynthesis 
catalyzes the synthesis of squalene 
from farnesyl-PP, downstream the 
mevalonate step 
Function 
Catalyzes the uptake of circulating 
LDLs 
Transmembrane multifunctional 
receptor for different ligands: 
oxLDLs, VLDL, collagen type I and 
IV, free fatty acids 
Scavenger receptor for oxLDLs in 
HSCs 
Regulators 
SREBP-2 ↑ HMGCoAR 
gene transcription 
miRNA34a: ↑ HMGCoAR 
dephosporylation and 
activation 
SREBP-2 ↑ squalene 
synthase gene transcription 
 
Regulators 
SREBP-2 ↑ LDL receptor 
expression 
Insulin ↑ CD36 translocation 
to PM 
 
LXR , PXR, PPAR- :↑ 
CD36 GENE  its 
transcription in the liver74 
PPAR- , curcumin: ↓ LOX-
1 expression 
Wnt signaling: ↑ LOX-1 
expression 52 
Localization 
Hepatocyte ER 
Hepatocyte ER 
Localization 
Transmembrane 
receptor in  
hepatocytes and 
macrophages 
Hepatocytes, 
macrophages, 
HSC, adipocytes 
HSCs, 
adipocytes, 
endothelial cells 
Factor 
HMGCoAR 
Squalene 
synthase 
Factor 
LDL receptor 
Cluster 
differentiation 
protein 36 
(CD36) 
lectin-like 
oxidized LDL 
receptor-
1(LOX-1)   
   
Biological effect 
SR-BI  is down-regulated in animal models of 
NASH14 
Intracellular cholesterol transport 
Biological effect 
Hepatic StAR expression was increased 7- and 15-
fold in steatosis and NASH patients, respectively11, 
thereby enhancing mitochondrial free cholesterol 
accumulation and toxicity 
Heterozygous  NPC1/2 deficiency leads to fatty 
liver, obesity and metabolic syndrome82 
 NPC1 gene is  linked to to early-onset  and morbid 
adult obesity in Europeans 83 
ORP8 ↓ hepatic cholesterol and triglyceride 
accumulation by inhibiting activation of SREBP-2 
and SREBP-1c 
 ORP8 ↑ hepatic insulin sensitivity through an AKT-
mediated mechanism86, 87  
Cholesterol absorption and secretion 
Biological effect 
NPC1L1 inhibition by ezetimibe reduces hepatic 
and intestinal free cholesterol absorption, reduces 
cellulat cholesterol overload, mitochondrial ROS 
generation and ER stress, improving NASH in 
animals and humans17-21, 92-95 
Function  
mediates the bi-directional, ATP-
independent transfer of cholesterol 
from HDL to hepatocytes and from 
hepatocytes to bile,  increasing 
reverse cholesterol transport and 
excretion into bile 
Function  
 cholesterol  transport from LE/LY 
to outer membrane of mitochondria  
and from the outer to the inner 
membrane of mitochondria 
Delivery of late endosome/lysosome 
free cholesterol to ER and other cellular 
compartments. 
 
Ccholesterol and oxysterol-binding 
proteins involved in nonvesicular 
cholesterol delivery from LE/LY, 
cholesterol transport between the ER 
and PM and inctracellular signalling.    
  
Function  
NPC1L1 mediates the uptake of free 
cholesterol from the bile by hepatocytes 
and from gut lumen by enterocytes  
 
INPC1L1 ↓ NPC2 activity, promoting 
LE/LY cholesterol overload 91 
 
 
Regulators 
SREBP-2: ↓ SR-BI gene  
expression 
 
Regulators 
SREBP-2: ↑ StARD4 
expression 
  
ER stress: ↑ StARD5 
expression77 
 miRNA33a: ↓  NPC1 gene 
expression109 
 
NPC1L1: ↓ NPC2 at 
posttranslational level  
 miRNA143: ↓ ORP8 in 
obesity87 
Regulators 
 SREBP-2, HNF-1  :  
↑ gene transcription 
 
LXR- , PPAR- , PPAR- : 
↓ gene transcription 
 
Localization 
Hepatocytes 
(both sinusoidal 
and canalicular 
membrane), 
macrophages 
Localization 
Endosomes and 
lysosomes of 
hepatocytes and 
steroidogenic 
cells 
LE/LY of a 
broad range of 
tissues 
Cytosol of 
hepatocytes and 
of broad range of 
tcells 
Localization 
Hepatocytes 
c(analicular 
membrane),  
enterocytes 
(apical 
membrane) 
Factor 
scavenger receptor class 
B type I  
(SR-BI) 
Factor 
Steroidogenic acute 
regulatory protein 
(StAR) 
Niemann-Pick  C1 (NPC1) 
and NPC2 proteins 
 
Oxysterol-binding proteins 
(OSBPs) and OSBP-related 
proteins (ORPs) 
 
Factor 
Niemann-Pick C1-like 1 
(NPC1L1) 
 
  
Biological effect 
Complete ABCA1 loss of function causes 
Tangier disease 
Hepatocyte ABCA1 expression is reduced in 
NASH patients 68 
Modulation of its activity affects the 
development of NASH in cellular and 
animal models 102 
ABCG5/G8 expression is reduced  in 
animal and human NASH14, 68 
 
Intracellular esterification and de-esterification 
Biological effect 
It promotes cholesterol excretion in the 
presence of an intact ABC transporter 
machinery.  
In NAFLD, hepatocyte ACAT-2 activity is 
mildly  increased11, 14 unchanged68 , or 
reduced105  
 
It promotes cholesterol excretion in the 
presence of intact ABC transporters; it 
enhances free cholesterol accumulation if 
cellular cholesterol export machinery is 
impaired 
In NAFLD patients, hepatocyte CEH 
activity is inappropriately elevated68   
Function  
In hepatocytes, ABCA1 catalyzes 
 cholesterol excretion to apoA-I to form 
HDL 
 
ABGC5 and ABCG8 form an 
heterodimer (ABCG5/G8) on the 
apical membrane of enterocytes and 
on the canalicular membrane of 
hepatocytes to excrete sterols into 
the intestinal lumen and the bile 
Function  
Rate-limiting enzyme for free 
cholesterol esterification to cholesteryl 
ester 
ER enzyme that hydrolyzes cholesteryl 
ester to free cholesterol 
 
Regulators 
miRNA33a: ↓ ABCA1 gene 
transcription109 
OSBPs, UFA :  ↓ ABCA1 
activity by accelerating protein 
degradation 102 
LXR- . ↑ ABCA1 gene 
transcription  
apoA-1: ↑ ABCA1 protein 
stability 
LXR- ,  HNF-4 , FXR: ↑ 
gene 
 Transcription110, 111, 116  
 
Regulators 
HNF1 , UFA, cholesterol : 
↑ ACAT-2 activity 
PPAR- ,  PPAR- : ↓ CEH 
gene transcription 
 
LXR- : ↑ CEH gene 
transcription 
 
 
Localization 
Hepatocytes, 
enterocytes, 
macrophages 
Hepatocytes, 
enterocytes, 
macrophages 
Localization 
ER of 
hepatocytes, 
enterocytes and 
macrophages 
ER of hepatocytes, 
enterocytes and 
macrophages 
Factor 
ATP-binding 
cassette  
transporter 
A1(ABCA1) 
ATP-binding 
cassette 
transporter G5/G8 
(ABCG5/G8) 
Factor 
acyl-CoA 
cholesterol:cholest
eryl transferase 
(ACAT)-2 
cholesteryl ester 
hydrolase (CEH) 
 
Intracellular metabolism to oxysterols and bile acids 
Biological effect 
CYP7A activity is reduced and its activity is 
inversely related to histological severity in NASH 14, 
68, 105
 
If excess 7OHC is excreted by hepatocytes 
through ABCG5/G8 transporters , it can directly 
activate hepatic macrophages and HSCs to secrete 
proinflammatory and profibrogenic cytokines38 
CYP27A1 activity is reduced and its activity is 
inversely related to histological severity in NASH 14, 
68, 105
 
27OHC administration reduced cholesterol 
accumulation in Kupffer cells and improved hepatic 
inflammation in NASH44 
 
Although a quantitatively minor precursor of bile 
acids, 25OHC is a potent regulator of lipid 
metabolism and inflammatory response. 
25OHC levels are increased in NAFLD patients 
and correlate with insulin resistance38 
25OHC promotes lipogenesis and inflammation, 
leading to NASH experimentally39-41 
25OHC3S had opposite effects than 25OHC on lipid 
metabolism and inflammation and improved NAFLD 
in cellular and mouse models(39-41 
 
Enhancement of on of SULT2B1b activity may 
counteract effects of toxic oxysterols 
 
Function 
CYP7A1 catalyzes the 7α-hydroxylation of 
cholesterol to 7α-hydroxycholesterol (7OHC),  the 
rate-limiting step in the neutral pathway to bile 
acid synthesis  
 
CYP27A1  catalizes the “alternative” (or acidic)   
pathway of bile acids synthesis, leading to 27-
hydroxycholesterol (27OHC) 
27OHC :  ↓ SREBP-2-activation and ↑ LXR- -
mediated transcription of ABC  transporters, 
thereby promoting cholesterol excretion 
It catalyzes cholesterol 
25-hydroxylation to 25-hydroxycholesterol 
(25OHC). 
25OHC enhances lipogenesis via 
LXR /SREBP-1c activation and inflammatory 
response via NF- B activation, leading to 
NASH39, 41 
Catalyzes 25OHC sulfation to  
25-hydroxycholesterol-3-sulfate (25OHC3S) 
Regulators 
Bile acids, insulin, SHP: ↓  
transcription of CYP7A1 
 
LXR , FXR, HNF-4 : ↑ 
transcription of CYP7A1 
Bile acids, insulin, LPS, IL-1, : 
↓  transcription of CYP27A1 
 
HNF-1 : ↑ transcription of 
CYP27A1 
LPS/TLR-4 pathway ↑ 
25OHC synthesis 
cAMP ↑ SULT2B1b 
expression 
Localization 
microsomal 
cytochrome 
P450 expressed 
only in 
hepatocytes 
 mitochondrial 
cytochrome P-450  
with  broad tissue  
distribution.:hepato
cytes,  endothelium, 
fibroblasts, 
macrophages 
 microsomal diiron 
cofactor  
enzyme,  not a  
cytochrome P450 
family, with broad 
tissue  distribution. 
Cytosolic 
enzyme 
Broad tissue  
distribution. 
Factor 
Sterol 7  
hydroxylase 
(CYP7A1)  
 
Sterol 27-
hydroxylase 
(CYP27A1) 
and in 
macrophages 
Sterol 25-
hydroxylase 
   
Hydroxysteroid 
sulfotransferase  
(SULT2B1b) 
 
 
Abbreviations: ABC. ATP-binding cassette; ER: endoplasmic reticulum;  FXR: farnesoid X-
receptor; HMGCoAR:  3-hydroxy-3-methyl-glutaryl-CoA reductase; HNF:   hepatocyte nuclear 
factor:; HSC: hepatic stellate cell;  IL-1: interleukin-1; LDL: low density lipoproteins;  
LE: late endosome; LY: lysosome; LPS: lipopolysaccharide, LXR: liver X-receptor; miRNA: 
microRNA; NPC1: Niemann-Pick C1;  
NPC2: Niemann-Pick C2; NPC1L1: Niemann-Pick C1-like 1; oxLDL: oxidized low density 
lipoproteins;  PM: plasma membrane; PP:  pyrophosphate; PPAR: peroxisome proliferator-activated 
receptor; PXR:   pregnane X receptor;  SHP: small heterodimeric partner;  
SNP: single nucleotide polymorphism; SREBP: sterol regulatory binding protein;  TLR-4: toll-like 
receptor-4; UFA: unsaturated fatty acids; VLDL. Very low density lipoproteins;  
 
Table 2 Nuclear regulators of cholesterol homeostasis potentially involved in NAFLD 
pathogenesis  
SREBP-2 
Cells Modulators Molecular targets Biological effect 
Hepatocytes, 
adipocytes 
Activators: 
IL-1b, IL-6,  SAA 
15
 , 
Insulin111 , 
PM cholesterol 
depletion60, 
 
Inhibitors: 
miRNA12269, 
7-OHC, 27-OHC109 
 LDL receptor 
↑ HMG-CoAR,  
↑ squalene synthase60 
 extracellular cholesterol 
uptake  
 cholesterol  synthesis 
 NPC1L1  cholesterol reabsorption 
from the intestine and bile 
StARD477  cholesterol transport to 
mitochondria 
↓ scavenger receptor class B type I 
(SR-BI)14 
↓ reverse cholesterol 
transport and elimination 
into bile 
adipocytes  
 secretion of proinflammatory 
adipokines (angiotensinogen, TNF-
, IL-6,  chemerin60, 65 
Chronic low-grade 
nflammation 
Insulin resistance 
miRNA33a 
Cells Modulators Molecular targets Biological effect 
Hepatocytes, 
adipocytes 
Same as SREBP-2 
 ABCA1109  cholesterol efflux 
 NPC-1109 Cholesterol 
accumulation in LE/LY 
 mitochondrial trifunctional protein 
hydroxyacyl-CoA dehydrogenase/  
3-ketoacyl-CoA thiolase/enoyl-CoA 
hydratase subunit (HADHB); 
 
↓carnitine palmitoyltransferase 1A 
(CPT1A);  
↓ carnitine O-octanoyltransferase 
(CROT) 110 
 mitochondrial fatty 
acid -oxidation 
Farnesoid X receptor (FXR) 
Cells modulators Molecular targets Biological effect 
Hepatocytes, 
Adipocytes, 
macrophages, 
enterocytes 
Activators: 
Natural bile acids 
(chenodeoxycholic 
acid),  
semisynthetic bile 
acids (obeticholic 
acid), 
PUFA (arachidonic, 
linolenic, or 
docosahexaenoic),  
synthetic 
agonists(GW4064, 
6α-ECDA, 
fexaramine)  
 
 CYP7A1,  
 ABCG5/G8115 
 bile acid synthesis and 
cholesterol excretion 
into bile 
↓  SREBP-1c-mediated lipogenesis  
(SHP-dependent and -independent 
mechanisms) 115 
 
 PPAR-α-mediated activation of fatty 
acid β-oxidation 115 
 
 ApoC-III and apoA-1 synthesis 
 ApoC-II synthesis and VLDL-
receptor expression 
 hepatic lipase activity115 
 
↓  liver triglyceride 
 
 
 
↓ secretion and   
clearance of  VLDL, 
thereby reducing plasma 
triglycerides  
  synthesis and uptake 
of HDL-C, with a net 
reduction in plasma 
HDL-C levels 
 
 hepatic expression of 
gluconeogenetic enzymes PEPCK, 
G6-Pase and fructose-1,6-
biphosphatase  
 IRS-1 phosphorylation and coupling 
with the  PI-3K activity115 
 hepatic 
gluconeogenesis 
 hepatic insulin 
sensitivity 
 Intestinal expression of antibacterial 
factors such as angiogenin, inducible 
nitric oxide synthase (iNOS) and 
IL18115 
Maintains gut integrity 
and impermeability to 
bacterial endotoxins 
 
 hepatic stellate cell expression of 
collagen α(1)I, α-smooth muscle actin, 
tissue inhibitors of metalloproteinase 1 
and 2 and TGF-β1 genes117 
 hepatic 
fibrogenesis117, 118 
 
  
   
Liver X receptor(LXR)-  
Cells modulators Molecular targets Biological effect 
Hepatocytes, 
enterocytes, 
Activators: 
glucose119 
↑ transcrioption of CYP7A1, the rate-
limiting enzyme of bile acid synthesis 
↑ cholesterol conversion 
to  bile acids 
macrophages 
 
natural oxysterols  
22(R)OHC, 
24(S)OHC, 
27OHC,  
 24(S), 25OOC 
Synthetic agonists 
GW3965, 
T0901317 
 
Inhibitors: 
natural oxysterol 
25OHC3S ,  
Synthetic oxysterol  
22(S)OHC 
40-42 
↓NPC1L1 114, 120 ↓ cholesterol 
reabsorption from the 
intestine and bile 
↑ macrophage,  intestinal and hepatic 
ABCG5/G8120 
↑ cholesterol reverse 
transport and excretion 
into bile and gut lumen 
↑  macrophage and hepatic ABCA1120 ↑ cholesterol efflux to 
acceptor apoa-I to form 
HDL-C 
↑  hepatic CEH120 ↑  FC availability for 
ABC transporters↑ 
cellular free cholesterol 
efflux 
↑  CD36 hepatocyte expression74 ↑ uptake of plasma 
oxLDLs and FFAs 
↑ LDLR ubiquitination and 
degradation121 
↓ uptake of plasma LDL 
↑ activation of sterol regulatory 
element-binding protein-c (SREBP-c), 
carbohydrate response 
element-binding protein (ChREBP) 
and their target enzymes fatty acid 
synthase(FAS), acyl coenzyme A 
carboxylase (ACC), and 
stearoyl CoA desaturase 1 (SCD-1) 124, 
125
 
↑ hepatic lipogenesis, 
steatosis and large  
VLDL secretion 
 secretion of angiopoietin-like 
protein 3 (Angptl3), an inhibitor of 
lippprotein lipase (LPL)126 
 VLDL catabolism 
↓  apoA-V secretion127 
 VLDL catabolism 
Macrophages 
Kupffer cells 
↓ activation and secretion of 
proinflammatory cytokines13, 124 
↓ hepatic inflammation 
in NASH 
Maintains gut integrity and 
impermeability to bacterial 
endotoxins122 
↓ endotoxin-mediated 
liver injury 
Hepatic 
stellate cells 
↓ HSC  activation and fibrogenesis123 ↓ hepatic fibrosis in 
NASH 
 
Abbreviations: ABC. ATP-binding cassette; CYP7A1:  Sterol 7  hydroxylase; 27OHC: 27-
hydroxycholesterol;  7OHC: 7-hydroxycholesterol; 22(R)OHC: 22(R)-hydroxycholesterol,  24(S): 
24(S)-hydroxycholesterol,  
27OHC: 27-hydroxycholesterol  24(S), 25OOC: 24(S), 25-epoxycholesterol 25OHC3S:25-
hydroxycholesterol-3-sulfate , 22(S)OHC: 22(S)-hydroxycholesterol;  
SAA: serum amyloid A protein; LE: late endosome; LY: lysosome;  
PM: plasma membrane; IL: interleukin; HMGCoAR:  3-hydroxy-3-methyl-glutaryl-CoA reductase;  
NPC1, NPC2: Niemann-Pick C1, C2; NPC1L1: Niemann-Pick C1-like 1; oxLDL: oxidized low 
density lipoproteins; PPAR: peroxisome proliferator-activated receptor;   SHP: small heterodimeric 
partner; StARD4: Steroidogenic acute regulatory protein D4; LE/LY: late endosomes/lysosomes; 
PEPCK: phosphoenol-pyruvate carboxykinase;  IRS-1: insulin-receptor substrate-1; TGF: 
transforming growth factor; CEH: cholesteryl ester hydrolase; LDLR: low density lipoprotein 
receptor; FFA: free fatty acids; HSC:hepatic stellate cells; VLDL: very low density lipoproteins
